Review



vancomycin minimum inhibitory concentration (mic) susceptibility breakpoint  (Clinical and Laboratory Standards Institute)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Clinical and Laboratory Standards Institute vancomycin minimum inhibitory concentration (mic) susceptibility breakpoint
    Vancomycin Minimum Inhibitory Concentration (Mic) Susceptibility Breakpoint, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vancomycin+minimum+inhibitory+concentration+(mic)+susceptibility+breakpoint/vancomycin+minimum+inhibitory+concentration++mic+/pmc04295319-22-11-3
    Average 90 stars, based on 1 article reviews
    vancomycin minimum inhibitory concentration (mic) susceptibility breakpoint - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Infection:

    Article Title: Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection
    Article Snippet: Patients were considered to have a vancomycin intermediate S. aureus (VISA) infection if S. aureus was isolated in culture and was determined to have a vancomycin minimum inhibitory concentration (MIC) of 4 or 8 μg/mL, in accordance with Clinical and Laboratory Standards Institute recommendations.

    Article Title: Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
    Article Snippet: In 2006, the Clinical and Laboratory Standards Institute (CLSI) established the vancomycin minimum inhibitory concentration (MIC) susceptibility breakpoint as 2 μg/mL for S. aureus while the definitions of VISA and vancomycin resistant S. aureus (VRSA) changed to MIC of 4 to 8 μg/mL and ≥ 16 μg/mL, respectively ( ).

    Article Title: Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.
    Article Snippet: Purpose To assess the relationship between high vancomycin minimum inhibitory concentrations (MIC), in patients with methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), and both mortality and complicated bacteremia.. Methods Embase, Medline, EBM, Scopus and Web of Science were searched for studies published from January 1st 2014 to February 29th 2020.. “High” vancomycin MIC cut off was defined as ≥ 1.5 mg/L.

    Article Title: Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
    Article Snippet: A 2013 surveillance study of over 2000 MRSA bloodstream isolates found less than 0.1% possessed a vancomycin minimum inhibitory concentration (MIC) of 4 μg/ml, the MIC that establishes MRSA as a vancomycin-intermediate susceptible Staphylococcus aureus (VISA) according to the Clinical and Laboratory Standards Institute (CLSI) [ ].

    Article Title: Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus
    Article Snippet: The clinical and laboratory standards institute (CLSI; formerly NCCLS) redefined the vancomycin breakpoints, suggesting a susceptible, intermediate, or resistant interpretation when the vancomycin minimum inhibitory concentration (MIC) is ≤ 2 μg/mL, 4 to 8 μg/mL, or ≥ 16 μg/mL, respectively ( ).

    Isolation:

    Article Title: Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection
    Article Snippet: Patients were considered to have a vancomycin intermediate S. aureus (VISA) infection if S. aureus was isolated in culture and was determined to have a vancomycin minimum inhibitory concentration (MIC) of 4 or 8 μg/mL, in accordance with Clinical and Laboratory Standards Institute recommendations.

    Article Title: Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
    Article Snippet: In 2006, the Clinical and Laboratory Standards Institute (CLSI) established the vancomycin minimum inhibitory concentration (MIC) susceptibility breakpoint as 2 μg/mL for S. aureus while the definitions of VISA and vancomycin resistant S. aureus (VRSA) changed to MIC of 4 to 8 μg/mL and ≥ 16 μg/mL, respectively ( ).

    Article Title: Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.
    Article Snippet: Purpose To assess the relationship between high vancomycin minimum inhibitory concentrations (MIC), in patients with methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), and both mortality and complicated bacteremia.. Methods Embase, Medline, EBM, Scopus and Web of Science were searched for studies published from January 1st 2014 to February 29th 2020.. “High” vancomycin MIC cut off was defined as ≥ 1.5 mg/L.

    Article Title: Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
    Article Snippet: A 2013 surveillance study of over 2000 MRSA bloodstream isolates found less than 0.1% possessed a vancomycin minimum inhibitory concentration (MIC) of 4 μg/ml, the MIC that establishes MRSA as a vancomycin-intermediate susceptible Staphylococcus aureus (VISA) according to the Clinical and Laboratory Standards Institute (CLSI) [ ].

    Article Title: Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus
    Article Snippet: The clinical and laboratory standards institute (CLSI; formerly NCCLS) redefined the vancomycin breakpoints, suggesting a susceptible, intermediate, or resistant interpretation when the vancomycin minimum inhibitory concentration (MIC) is ≤ 2 μg/mL, 4 to 8 μg/mL, or ≥ 16 μg/mL, respectively ( ).

    Concentration Assay:

    Article Title: Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection
    Article Snippet: Patients were considered to have a vancomycin intermediate S. aureus (VISA) infection if S. aureus was isolated in culture and was determined to have a vancomycin minimum inhibitory concentration (MIC) of 4 or 8 μg/mL, in accordance with Clinical and Laboratory Standards Institute recommendations.

    Article Title: Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
    Article Snippet: In 2006, the Clinical and Laboratory Standards Institute (CLSI) established the vancomycin minimum inhibitory concentration (MIC) susceptibility breakpoint as 2 μg/mL for S. aureus while the definitions of VISA and vancomycin resistant S. aureus (VRSA) changed to MIC of 4 to 8 μg/mL and ≥ 16 μg/mL, respectively ( ).

    Article Title: Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.
    Article Snippet: Purpose To assess the relationship between high vancomycin minimum inhibitory concentrations (MIC), in patients with methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), and both mortality and complicated bacteremia.. Methods Embase, Medline, EBM, Scopus and Web of Science were searched for studies published from January 1st 2014 to February 29th 2020.. “High” vancomycin MIC cut off was defined as ≥ 1.5 mg/L.

    Article Title: Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
    Article Snippet: A 2013 surveillance study of over 2000 MRSA bloodstream isolates found less than 0.1% possessed a vancomycin minimum inhibitory concentration (MIC) of 4 μg/ml, the MIC that establishes MRSA as a vancomycin-intermediate susceptible Staphylococcus aureus (VISA) according to the Clinical and Laboratory Standards Institute (CLSI) [ ].

    Article Title: Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus
    Article Snippet: The clinical and laboratory standards institute (CLSI; formerly NCCLS) redefined the vancomycin breakpoints, suggesting a susceptible, intermediate, or resistant interpretation when the vancomycin minimum inhibitory concentration (MIC) is ≤ 2 μg/mL, 4 to 8 μg/mL, or ≥ 16 μg/mL, respectively ( ).



    Similar Products

    90
    Clinical and Laboratory Standards Institute vancomycin minimum inhibitory concentration (mic) susceptibility breakpoint
    Vancomycin Minimum Inhibitory Concentration (Mic) Susceptibility Breakpoint, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vancomycin+minimum+inhibitory+concentration+(mic)+susceptibility+breakpoint/vancomycin+minimum+inhibitory+concentration++mic+/pmc04295319-22-11-3
    Average 90 stars, based on 1 article reviews
    vancomycin minimum inhibitory concentration (mic) susceptibility breakpoint - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results